Abstract：With the widespread use of various new antineoplastic agents in clinic, there are more and more reports of posterior reversible encephalopathy syndrome associated with new antineoplastic agents. The pathogenesis of new antineoplastic agent-related PRES is mainly related to endothelial dysfunction. The clinical manifestations of new antineoplastic agent-related PRES are lack of specificity, including headache, confusion, visual loss, visual field defect, seizure, and focal neurological deficit, etc. Imaging examinations in some patients show reversible bilateral subcortical angiogenic oedema, which is regarded as typical imaging findings. At present, unified diagnostic criteria of PRES have not been formulated. The core of the treatment is dose reduction or drug withdrawal, and other symptomatic treatments such as blood pressure control and anti-epileptic treatment are also necessary. The prognosis is good in most patients if timely treatment is given.
叶红，李军杰，武力勇. 重视新型抗肿瘤药物相关可逆性后部脑病综合征[J]. 药物不良反应杂志, 2021, 23(5): 225-227.
Ye Hong, Li Junjie, Wu liyong. Pay attention to the new antineoplastic agent-related posterior reversible encephalopathy syndrome. Adverse Drug Reactions Journal, 2021, 23(5): 225-227.
